Decision-making for bilateral risk-reducing mastectomy for an increased lifetime breast cancer risk: A qualitative metasynthesis
- PMID: 38429973
- DOI: 10.1002/pon.6311
Decision-making for bilateral risk-reducing mastectomy for an increased lifetime breast cancer risk: A qualitative metasynthesis
Abstract
Objective: Previvor is a term applied to a person with an identified, elevated lifetime cancer risk but without an actual cancer diagnosis. Previvorship entails the selection of risk management strategies. For women with a genetic mutation that increases their predisposition for a breast cancer diagnosis, bilateral risk-reducing mastectomy (BRRM) is the most effective prevention strategy. However, BRRM can change a woman's breast appearance and function. The purpose of this qualitative metasynthesis (QMS) was to better understand the decision-making process for BRRM among previvors.
Methods: A theory-generating QMS approach was used to analyze and synthesize qualitative findings. Research reports were considered for inclusion if: (1) women over 18 years of age possessed a genetic mutation increasing lifetime breast cancer risk or a strong family history of breast cancer; (2) the sample was considering, or had completed, BRRM; (3) the results reported qualitative findings. Exclusion criteria were male gender, personal history of breast cancer, and research reports which did not separate findings based on cancer diagnosis and/or risk-reduction surgery.
Results: A theory and corresponding model emerged, comprised of seven themes addressing the decision-making process for or against BRRM. While some factors to decision-making were decisive for surgery, others were more indefinite and contributed to women changing, processing, or suspending their decision-making for a period of time.
Conclusions: Regardless of the decision previvors make about BRRM, physical and psychosocial well-being should be considered and promoted through shared decision-making in the clinical setting.
Keywords: BRCA gene and oncology; breast cancer risk management; decision-making in breast cancer; genetic predisposition to breast cancer; hereditary breast and ovarian cancer syndrome; prophylactic mastectomy to decrease cancer risk.
© 2024 John Wiley & Sons Ltd.
References
REFERENCES
-
- Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055-1062. Epub 2004 Feb 23. https://doi.org/10.1200/JCO.2004.04.188
-
- Breast Cancer Risk Factors You Cannot Change [Internet]. American Cancer Society; 2021. https://www.cancer.org/content/dam/CRC/PDF/Public/8578.00.pdf
-
- McCarthy CM, Hamill JB, Kim HM, Qi J, Wilkins E, Pusic AL. Impact of bilateral prophylactic mastectomy and immediate reconstruction on health-related quality of life in women at high risk for breast carcinoma: results of the mastectomy reconstruction outcomes consortium study. Ann Surg Oncol. 2017;24(9):2502-2508. Epub 2017 Jun 13. https://doi.org/10.1245/s10434-017-5915-2
-
- Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243-2257. Epub 2015 May 27. https://doi.org/10.1056/NEJMsr1501341
-
- Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416. https://doi.org/10.1001/jama.2017.7112
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical